Short- chain fatty acids stimulate glucagon- like peptide-1 secretion via the G- proteincoupled receptor FFAR2
Insurance coverage can vary widely depending on your provider and plan
The theoretical 3-8% additional weight loss from adding cagrilintide to tirzepatide doesn't justify the significantly amplified side effects, 2-3x higher cost ($1,200-2,400 monthly), lack of physician support for experimental protocols, and unknown long-term safety profile
What we care about clinically falls, disability, frailty progression, all-cause mortality depends more on function than on mass per se
Although GLP-1 drugs are often used as long-term maintenance therapy because stopping them commonly leads to weight regain, there is still limited data on their effects over a full lifespan in older adults, especially frail older adults